Current dosing practices for perioperative factor VIII concentrate treatment in mild haemophilia A patients result in FVIII levels above target.

Lisette M SchütteNils de RooijHendrika C A M HazendonkRon A A MathôtReinier M van HestFrank W G LeebeekMarjon H CnossenMarieke J H A Kruip

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2019)

Dosing above FVIII target ranges with FVIII concentrates occurs frequently during perioperative treatment of mild HA patients. These results underline the necessity for better patient-tailored treatment.

Keyphrases

end stage renal disease
newly diagnosed
chronic kidney disease
prognostic factors
healthcare
primary care
patients undergoing
peritoneal dialysis
patient reported outcomes
replacement therapy
patient reported